Cohance Lifesciences Limited (NSE:COHANCE)
India · Delayed Price · Currency is INR | Market Cap | 165.08B -60.0% |
| Revenue (ttm) | 22.69B -14.0% |
| Net Income | 1.79B -63.2% |
| EPS | 4.68 -63.1% |
| Shares Out | 382.57M |
| PE Ratio | 92.20 |
| Forward PE | 61.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 773,766 |
| Open | 431.05 |
| Previous Close | 431.50 |
| Day's Range | 427.10 - 444.30 |
| 52-Week Range | 266.70 - 1,121.15 |
| Beta | 0.65 |
| Analysts | Hold |
| Price Target | 516.78 (+20.35%) |
| Earnings Date | May 12, 2026 |
About Cohance Lifesciences
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores... [Read more]
Financial Performance
In fiscal year 2026, Cohance Lifesciences's revenue was 23.03 billion, an increase of 92.27% compared to the previous year's 11.98 billion. Earnings were 1.79 billion, a decrease of -33.09%.
Financial StatementsNews
Cohance Lifesciences Transcript: Q4 25/26
FY 2026 saw a 13% revenue decline due to destocking, shipment delays, and site disruptions, but gross margins remained strong at 70.8%. Growth is expected to return in H2 FY 2027, driven by new product launches, improved utilization, and a diversified pipeline.
Cohance Lifesciences Quarterly report: Q4 2026
Cohance Lifesciences has published its Q4 2026 quarterly earnings report on May 12, 2026.
Cohance Lifesciences Slides: Q4 2026
Cohance Lifesciences has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 12, 2026.
Cohance Lifesciences Transcript: Q3 25/26
FY 2026 saw revenue and EBITDA declines due to timing, product mix, and regulatory issues, but gross margins improved and free cash flow remained strong. Management expects growth to resume in FY 2027, supported by a robust pipeline and ongoing investments in technology and compliance.
Cohance Lifesciences Quarterly report: Q3 2026
Cohance Lifesciences has published its Q3 2026 quarterly earnings report on February 12, 2026.
Cohance Lifesciences Slides: Q3 2026
Cohance Lifesciences has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 12, 2026.
Cohance Lifesciences Transcript: Q2 25/26
Revenue declined 8% year-on-year in Q2 FY2026 due to shipment deferrals, but material margins improved and adjusted for restocking, growth was 14%. FY2026 revenue is expected to be flat versus FY2025, with H2 anticipated to be stronger. Biotech funding headwinds and plant issues remain key risks.
Cohance Lifesciences Quarterly report: Q2 2026
Cohance Lifesciences has published its Q2 2026 quarterly earnings report on November 12, 2025.
Cohance Lifesciences Slides: Q2 2026
Cohance Lifesciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 12, 2025.
Cohance Lifesciences Transcript: Q1 25/26
Q1 FY 2026 saw 30% revenue growth, strong customer engagement, and major investments in ADC and oligonucleotide capacity. Guidance for FY 2026 and 2030 remains firm, with niche technology and differentiated platforms driving future growth.
Cohance Lifesciences Quarterly report: Q1 2026
Cohance Lifesciences has published its Q1 2026 quarterly earnings report on August 13, 2025.
Cohance Lifesciences Slides: Q1 2026
Cohance Lifesciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 13, 2025.